Archive

Category: AI drug discovery

Biotech startup with AlphaGo-type AI approach snags $30M

The CEO of Anagenex believes that the company’s AI engine trained on billions of data points and iterative testing will blow other AI drug discovery startups out of the water.

GSK joins LifeMine’s $175M funding as partners revive fungi as a drug discovery frontier

LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.

Creyon Bio gets some green for a new take on AI and genetic meds R&D

Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims it’s technology can provide sufficient safety and toxicity to enable a therapy to bypass the animal research currently needed before clinical trials.

Flagship’s Vesalius launches with $75M to take AI into realm of common diseases

Artificial intelligence is a powerful tool for rare disease drug discovery. The founders of Vesalius Therapeutics say AI and machine learning can also be applied to common diseases, and the startup has launched with $75 million in committed financing.

Insilico’s AI-discovered, AI-designed IPF drug enters Phase 1 trials

Hong Kong-based Insilico Medicine has begun a Phase 1 trial of its AI-discovered and AI-designed anti-fibrotic small molecule inhibitor. Currently referred to as ISM001-055, the drug is meant to treat ideopathic pulmonary fibrosis using a relatively novel mechanism of action. Insilico announced in February of last year that they had identified and developed the molecule […]

AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D

Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A financing will support R&D initially in immunology; the first Terray molecule is expected to reach the clinic in 18 months.

With 3 inflammation drugs on path to the clinic, Ventus Therapeutics adds $140M

Ventus Therapeutics’ lead programs address pathways associated with inflammation. Led by CEO Marcelo Bigal, the biotech discovers its drugs using computational analysis to understand the structure of proteins and find small molecules that can hit these “undruggable” targets.

Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia

Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.

DeepMind has unlocked protein-based medicine – what does that mean for drug patents?

One of science’s great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind’s discoveries while protecting their own?

HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie

Startup HiberCell has acquired Genuity Science, a marriage that brings together two companies that apply AI and machine learning to drug research. HiberCell says Genuity will help the company identify and validate new pathways in how cancer starts and progresses.

AI-driven Deep Genomics gets $180M to turn biology into informational medicines

Softbank led the Series C round of funding for Deep Genomics, a startup that applies its artificial intelligence technology to all aspects of discovering and developing new drugs. The Deep Genomics platform has yielded 10 programs; CEO Brendan Frey aims to advance four of them to the clinic in two years, all while tripling the […]

Archive

Biotech startup with AlphaGo-type AI approach snags $30M

GSK joins LifeMine’s $175M funding as partners revive fungi as a drug discovery frontier

Creyon Bio gets some green for a new take on AI and genetic meds R&D

Flagship’s Vesalius launches with $75M to take AI into realm of common diseases

Insilico’s AI-discovered, AI-designed IPF drug enters Phase 1 trials

AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D

With 3 inflammation drugs on path to the clinic, Ventus Therapeutics adds $140M

Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia

DeepMind has unlocked protein-based medicine – what does that mean for drug patents?

HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie

AI-driven Deep Genomics gets $180M to turn biology into informational medicines

Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies

How AI may hold the key to faster rare disease diagnosis

2021’s crystal ball: 6 AI predictions that will shape a new commercial model

Is the biopharma industry right to be skeptical about AI?

AI drug-discovery firm lands first partnership

Pandemic speeds up Novartis’ transformation